• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor alpha biologics and switched to ustekinumab.

作者信息

Downs A M R

出版信息

Br J Dermatol. 2010 Aug;163(2):433-4. doi: 10.1111/j.1365-2133.2010.09832.x. Epub 2010 Apr 29.

DOI:10.1111/j.1365-2133.2010.09832.x
PMID:20456344
Abstract
摘要

相似文献

1
Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor alpha biologics and switched to ustekinumab.
Br J Dermatol. 2010 Aug;163(2):433-4. doi: 10.1111/j.1365-2133.2010.09832.x. Epub 2010 Apr 29.
2
Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies.在抗肿瘤坏死因子疗法失败后，乌司奴单抗可迅速清除红皮病型银屑病。
Br J Dermatol. 2010 May;162(5):1144-6. doi: 10.1111/j.1365-2133.2010.09669.x. Epub 2010 Mar 6.
3
Consecutive use of different biological therapies in the treatment of psoriasis.连续使用不同生物疗法治疗银屑病。
Br J Dermatol. 2007 Aug;157(2):394. doi: 10.1111/j.1365-2133.2007.07988.x. Epub 2007 Jun 6.
4
Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.对使用依那西普治疗失败的中度至重度银屑病患者改用阿达木单抗：一项回顾性病例队列研究。
Br J Dermatol. 2010 Oct;163(4):889-92. doi: 10.1111/j.1365-2133.2010.09893.x. Epub 2010 Jul 28.
5
Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies.在抗肿瘤坏死因子治疗失败后，优特克单抗在难治性红皮病型银屑病中的持续疗效。
J Dermatol. 2012 Aug;39(8):730-1. doi: 10.1111/j.1346-8138.2011.01499.x. Epub 2012 Feb 27.
6
Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.生物制剂序贯疗法治疗中重度斑块状银屑病。
Br J Dermatol. 2012 Nov;167 Suppl 3:12-20. doi: 10.1111/j.1365-2133.2012.11209.x.
7
Diagnosing latent tuberculosis infection in patients with psoriasis under antitumour necrosis factor-α treatment: every new solution breeds new doubts.在接受抗肿瘤坏死因子-α治疗的银屑病患者中诊断潜伏性结核感染：每一种新方法都会引发新的疑问。
Br J Dermatol. 2011 Jan;164(1):208-9. doi: 10.1111/j.1365-2133.2010.10028.x. Epub 2010 Nov 4.
8
Combination of antitumour necrosis factor-α and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study.抗肿瘤坏死因子-α与抗白细胞介素-12/23抗体联合治疗难治性银屑病和银屑病关节炎：一项长期病例系列观察研究。
Br J Dermatol. 2016 May;174(5):1145-6. doi: 10.1111/bjd.14270. Epub 2016 May 4.
9
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.乌司奴单抗与依那西普治疗中重度银屑病的比较。
N Engl J Med. 2010 Jan 14;362(2):118-28. doi: 10.1056/NEJMoa0810652.
10
Combination therapy of biologics with traditional agents in psoriasis.生物制剂与传统药物联合治疗银屑病。
Skin Therapy Lett. 2011 Jun;16(6):1-3.

引用本文的文献

1
Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry.在CorEvitas银屑病登记处中接受司库奇尤单抗和其他生物制剂治疗的司库奇尤单抗患者的治疗结果。
Dermatol Ther (Heidelb). 2022 Dec;12(12):2797-2815. doi: 10.1007/s13555-022-00834-7. Epub 2022 Nov 4.
2
A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis.《中重度斑块状银屑病生物制剂转换治疗的研究进展》
Clin Drug Investig. 2018 Mar;38(3):191-199. doi: 10.1007/s40261-017-0603-3.
3
Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
银屑病二线生物疗法药物生存差异：来自英国皮肤科医师协会生物干预注册处（BADBIR）的观察性队列研究。
J Invest Dermatol. 2018 Apr;138(4):775-784. doi: 10.1016/j.jid.2017.09.044. Epub 2017 Dec 6.
4
An evolution in switching therapy for psoriasis patients who fail to meet treatment goals.针对未达治疗目标的银屑病患者，转换治疗方案的一种演变。
Dermatol Ther. 2015 Nov-Dec;28(6):390-403. doi: 10.1111/dth.12267. Epub 2015 Aug 10.